



15th May 2007

Febuxostat

The New Therapies Subgroup discussed the above drug at a meeting on the 15th May 2007. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMMG considered the therapeutic use of febuxostat for the treatment of gout.

The group recommend that febuxostat is considered as a treatment option for patients who are genuinely sensitive or allergic to allopurinol or for whom allopurinol is not considered suitable due to severe renal impairment. Allopurinol remains the first line treatment choice for gout.

Note that febuxostat has not yet been marketed in the UK.

Review Date: May 2009

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.